Insider Transactions in Q3 2022 at Entasis Therapeutics Holdings Inc. (ETTX)
Insider Transaction List (Q3 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 11
2022
|
Innoviva, Inc. |
BUY
Open market or private purchase
|
Indirect |
7,598,814
+20.61%
|
$15,197,628
$2.2 P/Share
|
|
Jul 11
2022
|
Kristie Ann Wagner VP, Principal Fin & Acct Off |
SELL
Sale (or disposition) back to the issuer
|
Direct |
80,500
-100.0%
|
-
|
|
Jul 11
2022
|
Anna Diaz Triola Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
125,000
-100.0%
|
-
|
|
Jul 11
2022
|
Ruben Tommasi Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
150,000
-100.0%
|
-
|
|
Jul 11
2022
|
Matthew Ronsheim Chief of Pharma Sciences & MFG |
SELL
Sale (or disposition) back to the issuer
|
Direct |
150,000
-100.0%
|
-
|
|
Jul 11
2022
|
Manoussos Perros President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
478,500
-100.0%
|
-
|
|
Jul 11
2022
|
John Patrick Mueller Chief Development Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
150,000
-100.0%
|
-
|
|
Jul 11
2022
|
David D. Meek Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
27,500
-100.0%
|
$55,000
$2.2 P/Share
|
|
Jul 11
2022
|
Howard Mayer Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
27,500
-100.0%
|
$55,000
$2.2 P/Share
|
|
Jul 11
2022
|
Elizabeth M Keiley General Counsel |
SELL
Sale (or disposition) back to the issuer
|
Direct |
150,000
-100.0%
|
-
|
|
Jul 11
2022
|
David C Hastings Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
27,500
-100.0%
|
$55,000
$2.2 P/Share
|
|
Jul 11
2022
|
Heather A. Berger Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
27,500
-100.0%
|
$55,000
$2.2 P/Share
|
|
Jul 11
2022
|
David Altarac Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
150,000
-100.0%
|
-
|
|
Jul 08
2022
|
Innoviva, Inc. |
BUY
Open market or private purchase
|
Indirect |
11,671,662
+35.0%
|
$23,343,324
$2.2 P/Share
|
|
Jul 07
2022
|
Ruben Tommasi Chief Scientific Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
39,596
-100.0%
|
$79,192
$2.2 P/Share
|
|
Jul 07
2022
|
Matthew Ronsheim Chief of Pharma Sciences & MFG |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
17,572
-100.0%
|
$35,144
$2.2 P/Share
|
|
Jul 07
2022
|
Manoussos Perros President and CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
56,072
-100.0%
|
$112,144
$2.2 P/Share
|
|
Jul 07
2022
|
John Patrick Mueller Chief Development Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
17,092
-100.0%
|
$34,184
$2.2 P/Share
|
|
Jul 07
2022
|
David D. Meek Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
22,000
-100.0%
|
$44,000
$2.2 P/Share
|
|
Jul 07
2022
|
Howard Mayer Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
22,000
-100.0%
|
$44,000
$2.2 P/Share
|
|
Jul 07
2022
|
Elizabeth M Keiley General Counsel |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
17,572
-100.0%
|
$35,144
$2.2 P/Share
|
|
Jul 07
2022
|
David C Hastings Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
22,000
-100.0%
|
$44,000
$2.2 P/Share
|
|
Jul 07
2022
|
Heather A. Berger Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
22,000
-100.0%
|
$44,000
$2.2 P/Share
|
|
Jul 07
2022
|
David Altarac Chief Medical Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
17,572
-100.0%
|
$35,144
$2.2 P/Share
|